Research Journal of Pharmacology and Pharmacodynamics

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Biomarker: Indicator for Disease


Affiliations
1 Govt. College of Pharmacy, Karad Dist. Satara-415124, M.S., India
     

   Subscribe/Renew Journal


Biomarkers are referred to every means of tools for quantifiable measurements of biological homeostasis, which distinguish what is abnormal from normal. In other words any accessible, quantifiable signal that informs about the state of health for biological system. This is a broad definition that encompasses a range of measurements - physical, biochemical and even questionnaires. Also it gives measure changes occur in blood, serum, plasma, enzyme, body fluid and any normal constituent in body, which indicates the disease condition.

Biomarkers also play a very important role in identification of cerebrovascular diseases like Alzheimer's, frontotemporal dementia (FTD), Pulmonary Hypertension, lung cancer, Thyroid cancer etc. Whatever the measurement, a good biomarker should possess specific characteristics and be subject to robust statistical analysis. The focus of this review will inform us the potential value of Biomarker in all above said. A biochemical test that indicates the presence of subclinical disease would allow early intervention and possibly a better chance of altering the course of the disease. Although there have been considerable advances, many areas of drug development still require kinetic biomarkers. In principle, biomarker can be developed for any system in which the rate of synthesis or degradation of a protein, lipid, carbohydrate, ribonucleotide or cell is desired. We emphasized on many target pathways of interest to pharmaceutical research and noted the potential for applying stable biomarkers.


Subscription Login to verify subscription
User
Notifications
Font Size


  • Steele, A., Beaty; et al. (September 26, 2006), "Final report of the MEPAG Astrobiology Field Laboratory Science Steering Group (AFL-SSG)", in Steele, Andrew (.doc), The Astrobiology Field Laboratory, U.S.A.: the Mars Exploration Program Analysis Group (MEPAG) - NASA, pp. 72.

  • Loukopoulos P, et al. Clinical and pathologic relevance of p53 index in canine osseous tumors. Veterinary Pathology 2003; 40:237-248.

  • Loukopoulos P, et al. Matrix metalloproteinase-2 and -9 involvement in canine tumors. Veterinary Pathology 2003; 40:382-394.

  • Medterms definition Ott, W. R., Steinemann, (2007).

  • Biomarkers of exposure. In W. R. Ott, A. C. Steinemann & L. A. Wallace (Eds.), Exposure analysis (pp. 395-404).

  • De Vicente, C., T. Fulton (2003). Molecular Marker Learning Modules - Vol. 1. IPGRI, Rome, Italy and Institute for Genetic Diversity, Ithaca, New York, USA.

  • Heyman A, et al. Cerebral infarcts in patients with autopsy-proven Alzheimer's disease: CERAD, part XVIII. Consortium to Establish a Registry for Alzheimer's Disease. Neurology 1998;51:159-62.

  • Snowdon DA, et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997;277:813-7.

  • Kalaria R. Similarities between Alzheimer's disease and vascular dementia. J Neurol Sci 2002;203-204:29-34.

  • Kalaria RN. The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease. Ann NY Acad Sci 1999;893:113-25.

  • Kalaria RN. Small vessel disease and Alzheimer's dementia: pathological considerations. Cerebrovasc Dis 2002;13 (Suppl 2):48-52.

  • Kalaria RN. Vascular factors in Alzheimer's disease. Int Psychogeriatr 2003;15 (Suppl 1):47-52.

  • Zimmerman RD, et al Periventricular hyperintensity as seen by magnetic resonance: prevalence and significance. AJR Am J Roentgenol 1986;146:443-50.

  • Tian J, et al. Relationships between arteriosclerosis, cerebral amyloid angiopathy and myelin loss from cerebral cortical white matter in Alzheimer's disease. Neuropathol Appl Neurobiol 2004;30:46-56.

  • Fazekas F, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 1993;43:1683-9.

  • Fazekas F, et al. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987;149: 351-6.

  • Scheltens P, et al. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 1993;114:7-12.

  • Fazekas F, et al. CT and MRI rating of white matter lesions. Cerebrovasc Dis 2002;13 Suppl 2:31-6.

  • Scheltens P, et al. White matter changes on CT and MRI: an overview of visual rating scales. European Task Force on Age-Related White Matter Changes. Eur Neurol 1998;39:80-9.

  • Baldwin RC. Is vascular depression a distinct sub-type of depressive disorder? A review of causal evidence. Int J Geriatr Psychiatry 2005;20:1-11.

  • Jellinger KA. The pathology of ischemic-vascular dementia: an update. J Neurol Sci 2002;203-204:153-7.

  • Esiri MM, et al Neuropathological assessment of the lesions of significance in vascular dementia. J Neurol Neurosurg Psychiatry 1997;63:749-53.

  • Hommel M, Gray F. Microvascular pathology. New York: Springer; 1995.

  • Poirier J, et al. Cerebral lacunae. A proposed new classification. Clin Neuropathol 1984;3:266.

  • Baldwin RC, O'Brien J. Vascular basis of late-onset depressive disorder. Br J Psychiatry 2002;180:157-60.

  • O'Brien JT, Ames D. White matter lesions in depression and Alzheimer's disease. Br J Psychiatry 1996;169:671.

  • Alexopoulos GS, et al "Vascular depression" hypothesis. Arch Gen Psychiatry 1997;54:915-22.

  • Derouesne C, Poirier J. Cerebral lacunae: still under debate. Rev Neurol (Paris) 1999;155:823-31.

  • Heier LA, et al. Large Virchow-Robin spaces: MRclinical correlation. AJNR Am J Neuroradiol 1989;10:929-36.

  • Braffman BH, et al pathologic correlation with gross and histopathology. 1. Lacunar infarction and Virchow-Robin spaces. AJR Am J Roentgenol 1988;151:551-8.

  • Machado MA, et al Dilatation of Virchow-Robzin spaces in patients with migraine. Arq Neuropsiquiatr 2001;59:206-9.

  • Fazekas F, et al. The morphologic correlate of incidental punctate white matter hyperintensities on MR images. AJNR Am J Neuroradiol 1991;12:915-21.

  • Ogawa T, et al. Unusual widening of Virchow-Robin spaces: MR appearance. AJNR Am J Neuroradiol 1995;16:1238-42.

  • Hughes W. Origin of lacunes. Lancet. 1965;1:19-21.

  • Benhaiem-Sigaux N, et al Expanding cerebellar lacunes due to dilatation of the perivascular space associated with Binswanger's subcortical arteriosclerotic encephalopathy. Stroke 1987;18:1087-92.

  • Derouesne C, "Expanding cerebral lacunae" in a hypertensive patient with normal pressure hydrocephalus. Neuropathol Appl Neurobiol 1987;13:309-20.

  • Pullicino PM, Miller LL, Alexandrov AV, Ostrow PT. Infraputaminal "lacunes". Clinical and pathological correlations. Stroke 1995;26:1598-602.

  • Aldred MA, et al. BMPR2 gene rearrangements account for a signiÞ cant proportion of mutations in familial and idiopathic bpulmonary arterial hypertension. Hum Mutat 2006;27:212-3.

  • Cogan JD, et al. High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. Am J RespirCrit Care Med 2006;174:590-8.

  • Lane KB, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-a receptor, cause familial primary pulmonary hypertension: The International PPH Consortium. Nat Genet 2000;26:81-4.

  • Machado RD, et al. Mutations of the TGF-a type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006;27:121-32.

  • Morisaki H, et al BMPR2 mutations found in Japanese patients with familial and sporadic primary pulmonary hypertension. Hum Mutat 2004;23:632.

  • Roberts KE, et al. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J 2004;24:371-4.

  • Harrison RE, et al. Molecular and functional analysis identiÞ es ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 2003;40:865-71.

  • Trembath RC. Mutations in the TGF-a type 1 receptor, ALK1, in combined primary pulmonary hypertension and hereditary haemorrhagic telangiectasia, implies pathway specip city. J Heart Lung Transplant 2001;20:175.

  • Trembath RC, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001;345:325-34.

  • Leuchte HH, et al. N-terminal pro-brain natriuretic peptide and renal insu. ciency as predictors of mortality in pulmonary hypertension. Chest 2007;131:402-9.

  • Blyth KG, et al. NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J 2007;29:737-44.

  • Souza R, et al NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respir Med 2007;101:69-75.

  • Leuchte HH, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006;173:744-50.

  • Alkowska A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006;129:1313-21.

  • Leuchte HH, et al. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. Chest 2005;128:2368-74.

  • Souza R, et al. N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension. Eur Respir J 2005;25:509-13.

  • Leuchte HH, et al. Clinical signiÞ cance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004;43:764-70.

  • Leuchte HH, et al. Brain natriuretic peptide and exercise capacity in lung Þ brosis and pulmonary hypertension. Am J Respir Crit Care Med 2004;170:360-5.

  • Nagaya N, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865-70.

  • Nagaya N, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998;31:202-8.

  • Sudoh T, et al A new natriuretic peptide in porcine brain. Nature 1988;33215:78-81.

  • Mukoyama M, et al. Brain natriuretic peptide as a novel cardiac hormone in humans: Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402-12.

  • Hama N, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995;92:1558-64.

  • Holmes SJ, et al Renal, endocrine, and hemodynamic e. ects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993;76:91-6.

  • Hall C. Essential biochemistry and physiology of (NT-pro) BNP. Eur J Heart Fail 2004;6:257-60.

  • Torbicki A, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003;108:844-8.

  • Nagaya N, et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 1999;160:487-92.

  • Nickel N, et al. Growth di. erentiation factor-15 in idiopathic pulmonary arteria hypertension. Am J Respir Crit Care Med 2008;178:534-41.

  • Shah SJ, et al Gomberg-Maitland M. Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension. Circulation 2008;117:2475-83.

  • Gharib H, Goellner JR: Fine-needle aspiration biopsy of the thyroid: An appraisal. Ann Intern Med 118:282-289, 1993.

  • Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer statistics,2001. CA Cancer J Clin 51:15-36, 2001.

  • Goellner JR, Gharib H, Grant CS, et al: Fine needle aspirationcytology of the thyroid, 1980 to 1986. Acta Cytol 31:587-590, 1987.

  • Caraway NP, Sneige N, Samaan NA: Diagnostic pitfalls in thyroid fine-needle aspiration: A review of 394 cases. Diagn Cytopathol 9:345-350, 1993.

  • Ravetto C, Colombo L, Dottorini ME: Usefulness of fine-needle aspiration in the diagnosis of thyroid carcinoma: A retrospective study in 37,895 patients. Cancer 90:357-363, 2000.

  • Wiseman SM, Baliski C, Irvine R, et al: Hemithyroidectomy: The optimal initial surgical approach for individuals undergoing surgery for a cytological diagnosis of follicular neoplasm. Ann Surg Oncol 13:425-432, 2006.

  • Griffith OL, et al: Assessment and integration of publicly available SAGE, cDNA microarray, and oligonucleotide microarray expression data for global coexpression analyses. Genomics 86:476-488, 2005.

  • Braunwald E, et al. ACC/AHA 2002 Guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction.

  • Bertrand ME, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2002;23:1809-1840.

  • Antman EM, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction.

  • Van de Werf F, et al. Management of acute myocardial infarction inpatients presenting with ST-segment elevation The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003;24:28-66.

  • Holvoet P. Oxidative modification of low-density lipoproteins in atherothrombosis. Acta Cardiol 1998;53:253-260.

  • Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001;286:2136-2142.

  • Wu AHB, et al. Ischemia modified albumin, free fatty acids, whole blood choline, B-type natriuretic peptide, glycogen phosphorylase BB, and cardiac troponin. Wu AHB eds. Cardiac markers 2003:259-278 Humana Press Totowa, NJ.

  • Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases; structure, function and biochemistry. Circ Res 2003;92:827-839.

  • Wald NJ et al Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy for the International Prenatal Screening Research Group. Br J Obstet Gynaecol 1996;103:407-412.

  • Lawrence JB, et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Nat Acad Sci U S A 1999;96:3149-3153.

  • Beaudeux JL, et al. Serum plasma pregnancy-associated protein A. A potential marker of echogenic carotid atherosclerotic plaques in asymptomatic hyperlipidemic subjects at high cardiovascular risk. Arterioscler Thromb Vasc Biol 2003;23:e7-e10.

  • Stulc T, et al. Increased levels of pregnancy associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment. Am Heart J 2003;146:e21.

  • Bayes-Genis A, et al. Insulin-like growth factor binding protein-4 protease produced by smooth muscle cells increases in the coronary artery after angioplasty. Arterioscler Thromb Vasc Biol 2001;21:335-341.

  • Baylin, S.B. (2005) DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol. 2 Suppl 1, S4-11. 20.

  • Belinsky, S.A. (2004) Gene-promoter hypermethylation as a biomarker in lung cancer. Nat. Rev. Cancer 4, 707-717.

  • Ludwig, J.A. and Weinstein, J.N. (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5, 845-856.

  • Wistuba, II, Lam, Set al. (1997) Molecular damage in the bronchial epithelium of current and former smokers. J. Natl. Cancer Inst. 89, 1366-1373.

  • Senchenko, V.N. et al Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas. Oncogene 23, 5719-5728.

  • Wiest, J.S., et al.(1997) Genetic markers for early detection of lung cancer and outcome measures for response to chemoprevention. J. Cell Biochem. Suppl. 28-29, 64-73.

  • Zabarovsky, E. et al (2002) Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 21, 6915-6935.

  • Xue, X., Zhu, Y.M. and Woll, P.J. (2006) Circulating DNA and lung cancer. Ann. N.Y. Acad. Sci. 1075, 154-164.

  • Mao, L., et al (1997) Clonal genetic alterations in the lungs of current and former smokers. J. Natl. Cancer Inst. 89, 857-862.

  • Wistuba, II, Behrens, et al (1999) Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 18, 643-650.

  • Chung, G.T.et al (1995) Sequential molecular genetic changes in lung cancer development. Oncogene 11, 2591-2598.

  • Belinsky, S.A., et al (1998) Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. U.S.A. 95, 11891-11896.

  • Chaussade, L., et al. (2001) Expression of p15 and p15.5 products in neuroendocrine lung tumours: relationship with p15(INK4b) methylation status. Oncogene 20, 6587-6596.

  • Esteller, M., et al. (1999) Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59, 67-70.

  • Kurakawa, E., et al. (2001) Hypermethylation of p16 (INK4a) and p15(INK4b) genes in non-small cell lung cancer. Int. J. Oncol. 19, 277-281.

  • Palmisano, W.A. et al. (2000) Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60, 5954-5958.

  • Virmani, A.K., et al (2000) Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J. Natl. Cancer Inst. 92, 1303-1307.

  • Zochbauer-Muller, et al. (2001) Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 61, 249-255. D.H. (2006) Cohypermethylation of p16, and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I nonsmall cell lung cancer. Cancer Res. 66, 4049-4054.


Abstract Views: 264

PDF Views: 0




  • Biomarker: Indicator for Disease

Abstract Views: 264  |  PDF Views: 0

Authors

Rupali Kirtawade
Govt. College of Pharmacy, Karad Dist. Satara-415124, M.S., India
Pallavi Salve
Govt. College of Pharmacy, Karad Dist. Satara-415124, M.S., India
Chhotaram Seervi
Govt. College of Pharmacy, Karad Dist. Satara-415124, M.S., India
Anita Kulkarni
Govt. College of Pharmacy, Karad Dist. Satara-415124, M.S., India
Pandurang Dhabale
Govt. College of Pharmacy, Karad Dist. Satara-415124, M.S., India

Abstract


Biomarkers are referred to every means of tools for quantifiable measurements of biological homeostasis, which distinguish what is abnormal from normal. In other words any accessible, quantifiable signal that informs about the state of health for biological system. This is a broad definition that encompasses a range of measurements - physical, biochemical and even questionnaires. Also it gives measure changes occur in blood, serum, plasma, enzyme, body fluid and any normal constituent in body, which indicates the disease condition.

Biomarkers also play a very important role in identification of cerebrovascular diseases like Alzheimer's, frontotemporal dementia (FTD), Pulmonary Hypertension, lung cancer, Thyroid cancer etc. Whatever the measurement, a good biomarker should possess specific characteristics and be subject to robust statistical analysis. The focus of this review will inform us the potential value of Biomarker in all above said. A biochemical test that indicates the presence of subclinical disease would allow early intervention and possibly a better chance of altering the course of the disease. Although there have been considerable advances, many areas of drug development still require kinetic biomarkers. In principle, biomarker can be developed for any system in which the rate of synthesis or degradation of a protein, lipid, carbohydrate, ribonucleotide or cell is desired. We emphasized on many target pathways of interest to pharmaceutical research and noted the potential for applying stable biomarkers.


References